全文获取类型
收费全文 | 1239篇 |
免费 | 56篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 49篇 |
妇产科学 | 83篇 |
基础医学 | 116篇 |
口腔科学 | 35篇 |
临床医学 | 107篇 |
内科学 | 231篇 |
皮肤病学 | 4篇 |
神经病学 | 210篇 |
特种医学 | 50篇 |
外科学 | 149篇 |
综合类 | 1篇 |
预防医学 | 39篇 |
眼科学 | 12篇 |
药学 | 140篇 |
肿瘤学 | 59篇 |
出版年
2024年 | 3篇 |
2023年 | 14篇 |
2022年 | 25篇 |
2021年 | 32篇 |
2020年 | 15篇 |
2019年 | 29篇 |
2018年 | 17篇 |
2017年 | 20篇 |
2016年 | 19篇 |
2015年 | 39篇 |
2014年 | 40篇 |
2013年 | 38篇 |
2012年 | 76篇 |
2011年 | 81篇 |
2010年 | 45篇 |
2009年 | 37篇 |
2008年 | 68篇 |
2007年 | 81篇 |
2006年 | 76篇 |
2005年 | 68篇 |
2004年 | 64篇 |
2003年 | 44篇 |
2002年 | 46篇 |
2001年 | 33篇 |
2000年 | 28篇 |
1999年 | 28篇 |
1998年 | 17篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 12篇 |
1994年 | 10篇 |
1993年 | 11篇 |
1992年 | 18篇 |
1991年 | 28篇 |
1990年 | 15篇 |
1989年 | 12篇 |
1988年 | 12篇 |
1987年 | 13篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 2篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1974年 | 2篇 |
排序方式: 共有1296条查询结果,搜索用时 31 毫秒
41.
42.
U. Martinowitz A. Shapiro D. V. Quon M. Escobar C. Kempton P. W. Collins P. Chowdary M. Makris P. M. Mannucci M. Morfini L. A. Valentino E. Gomperts M. Lee 《Haemophilia》2012,18(6):881-887
IB1001 trenacog alfa is an investigational recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with haemophilia B. To compare the pharmacokinetics (PK) of IB1001 with nonacog alfa in individuals with haemophilia B and to assess the relationship between sialylation and PK of IB1001 (NCT00768287). A randomized, double‐blind, non‐inferiority, cross‐over study conducted in participants aged ≥12 years weighing ≥40 kg, with severe or moderately severe haemophilia B (FIX activity ≤2 IU dL ?1). PK parameters were derived using observed FIX concentration levels and actual PK sampling times, and repeated in a subset of participants who had received IB1001 prophylaxis for 4–18 months. A retrospective analysis was conducted in subgroups according to the sialylation levels of IB1001 (50.8, 57.8–59.0%, or 71.7%). In the 32 adolescent and adult males evaluated, there were no clinically meaningful differences in PK parameters between those receiving IB1001 75 IU kg?1 or nonacog alfa. The lower limit of the one‐sided 95% confidence interval for the ratio of AUC0‐t and AUC0‐∞ (IB1001/nonacog alfa) was 0.90, establishing non‐inferiority. Terminal phase half‐lives were similar (29.7 ± 18.2 h for IB1001 and 33.4 ± 21.2 h for nonacog alfa). The PK results were stable for up to 18 months of IB1001 exposure; the impact of sialylation levels was not clinically meaningful. There were no clinically meaningful PK differences between IB1001 and nonacog alfa. IB1001 was well tolerated and without safety concerns. The non‐inferiority of IB1001 to nonacog alfa supports IB1001 becoming a useful alternative recombinant agent for the management of haemophilia B. 相似文献
43.
Montano V. Orsucci D. Carelli V. La Morgia C. Valentino M. L. Lamperti C. Marchet S. Musumeci O. Toscano A. Primiano G. Santorelli F. M. Ticci C. Filosto M. Rubegni A. Mongini T. Tonin P. Servidei S. Ceravolo R. Siciliano G. Mancuso Michelangelo 《Journal of neurology》2022,269(3):1413-1421
Journal of Neurology - Both prevalence and clinical features of the various movement disorders in adults with primary mitochondrial diseases are unknown. Based on the database of the... 相似文献
44.
45.
Michelangelo Mancuso Daniele Orsucci Corrado Angelini Enrico Bertini Michela Catteruccia Elena Pegoraro Valerio Carelli Maria L. Valentino Giacomo P. Comi Carlo Minetti Claudio Bruno Maurizio Moggio Elena Caldarazzo Ienco Tiziana Mongini Liliana Vercelli Guido Primiano Serenella Servidei Paola Tonin Mauro Scarpelli Antonio Toscano Olimpia Musumeci Isabella Moroni Graziella Uziel Filippo M. Santorelli Claudia Nesti Massimiliano Filosto Costanza Lamperti Massimo Zeviani Gabriele Siciliano 《Movement disorders》2014,29(6):722-728
Myoclonus is a possible manifestation of mitochondrial disorders, and its presence is considered, in association with epilepsy and the ragged red fibers, pivotal for the syndromic diagnosis of MERRF (myoclonic epilepsy with ragged red fibers). However, its prevalence in mitochondrial diseases is not known. The aims of this study are the evaluation of the prevalence of myoclonus in a big cohort of mitochondrial patients and the clinical characterization of these subjects. Based on the database of the “Nation‐wide Italian Collaborative Network of Mitochondrial Diseases,” we reviewed the clinical and molecular data of mitochondrial patients with myoclonus among their clinical features. Myoclonus is a rather uncommon clinical feature of mitochondrial diseases (3.6% of 1,086 patients registered in our database). It is not strictly linked to a specific genotype or phenotype, and only 1 of 3 patients with MERRF harbors the 8344A>G mutation (frequently labeled as “the MERRF mutation”). Finally, myoclonus is not inextricably linked to epilepsy in MERRF patients, but more to cerebellar ataxia. In a myoclonic patient, evidences of mitochondrial dysfunction must be investigated, even though myoclonus is not a common sign of mitochondriopathy. Clinical, histological, and biochemical data may predict the finding of a mitochondrial or nuclear DNA mutation. Finally, this study reinforces the notion that myoclonus is not inextricably linked to epilepsy in MERRF patients, and therefore the term “myoclonic epilepsy” seems inadequate and potentially misleading. © 2014 International Parkinson and Movement Disorder Society 相似文献
46.
47.
Andrea Scaramuzza Valentino Cherubini Stefano Tumini Riccardo Bonfanti Pietro Buono Francesca Cardella Giuseppe d’Annunzio Anna Paola Frongia Fortunato Lombardo Anna Carla Maria Monciotti Ivana Rabbone Riccardo Schiaffini Sonia Toni Stefano Zucchini Giulio Frontino Dario Iafusco 《Acta diabetologica》2014,51(2):173-184
A panel of experts of the Italian Society of Pediatric Endocrinology and Diabetology comprehensively discussed and approved the Italian recommendations regarding self-monitoring of blood glucose, continuous glucose monitoring and other measures of glycemic control in children and adolescents with type 1 diabetes. After an extensive review of the literature, we took these issues into account: self-monitoring blood glucose, continuous glucose monitoring, glycemic variability, glycosuria, ketonuria, ketonemia, glycated hemoglobin, fructosamine and glycated albumin, logbook, data downloading, lancing devices, carbohydrate counting, and glycemic measurements at school. We concluded that clinical guidelines on self-management should be developed in every country with faithful adaptation to local languages and taking into account specific contexts and local peculiarities, without any substantial modifications to the international recommendations. We believe that the National Health Service should provide all necessary resources to ensure self-monitoring of blood glucose and possibly continuous glucose monitoring of all children and adolescents with type 1 diabetes, according to the standards of care provided by these recommendations and internationally. 相似文献
48.
Dario Cocito Aristide Merola Erdita Peci Anna Mazzeo Raffaella Fazio Ada Francia Paola Valentino Rocco Liguori Massimiliano Filosto Gabriele Siciliano Angelo Maurizio Clerici Stefania Lelli Girolama Alessandra Marfia Giovanni Antonini Ilaria Cecconi Eduardo Nobile-Orazio Leonardo Lopiano SCIg Chronic Dysimmune Neuropathies Italian Network 《Journal of neurology》2014,261(11):2159-2164
This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient’s perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient’s perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period. 相似文献
49.
50.
Elena Massa Clelia Donisi Nicole Liscia Clelia Madeddu Valentino Impera Stefano Mariani Mario Scartozzi Eleonora Lai 《Clin Pract Epidemiol Ment Health》2021,17(1):295
Background:Depression is a common psychiatric problem in the elderly and oncology patients. In elderly people with cancer, depression has a peculiar phenomenology. It has a significant impact on the quality of life. Moreover, it is associated with poor adherence to treatments, increased risk of suicide, and mortality. Nevertheless, the topic of depression in elderly people with cancer remains unexplored.Objective:The main goal of this article is to review the literature from the past 20 years on the relationships between depression, cancer, and aging.Methods:The methods followed the Prisma model for eligibility of studies. The articles in which the keywords “depression”, “cancer”, “ elderly, aging, or geriatric” were present, either in the text or in the abstract, were selected. 8.056 articles, by matching the keywords “depression and elderly and cancer,” were identified. Only 532 papers met the eligibility criteria of search limits and selection process. Out of 532 papers, 467 were considered irrelevant, leaving 65 relevant studies. Out of 65 suitable studies, 39 (60.0%) met our quality criteria and were included.Results:The risk factors associated with depression in elderly people with cancer can be divided into 4 groups: 1) tumor-related; 2) anticancer treatment-related; 3) patients-related; 4) number and type of comorbidity. The main obstacles in diagnosing depression in elderly patients with cancer are the overlap of the symptoms of cancer and side effects of treatment with the symptoms of depression but also the different ways of reporting depressive symptoms of elderly people and the different clinical types of depression. There is a lack of data regarding validated scales to assess depression in geriatric patients with cancer. Any mental illness, specifically co-occurring anxiety and depression, increases the risk of diagnosis delay and anticancer treatment adherence. Cancer and the diagnosis of mental disorders prior to cancer diagnosis correlate with an increased risk for suicide. A non-pharmacological therapeutic approach, pharmacological treatment and/or a combination of both can be used to treat elderly patients with cancer, but a detailed analysis of comorbidities and the assessment of polypharmacy is mandatory in order to avoid potential side-effects and interactions between antidepressants and the other drugs taken by the patients.Conclusion:Future research should be conducted with the aim of developing a modified and adapted assessment method for the diagnosis and treatment of depression in elderly people with cancer in order to improve their clinical outcomes and quality of life. 相似文献